Supernus, Inc. SUPN
SUPN Rating
SUPN Rating Factors
SUPN Company Overview
Indivior PLC is a global specialty pharmaceutical company focused primarily on developing, manufacturing, and commercializing treatments for substance use disorders and serious mental illnesses. The company operates within the biopharmaceutical and addiction treatment industries, with a strategic emphasis on opioid use disorder (OUD) therapies, schizophrenia treatments, and related central nervous system (CNS) conditions. Its principal revenue drivers have historically included SUBLOCADE, an extended-release injectable buprenorphine treatment for OUD, and legacy products such as SUBOXONE Film. The company serves healthcare providers, treatment centers, government agencies, managed care organizations, and patients across multiple international markets.
Indivior originated as a business unit within Reckitt Benckiser before becoming an independent publicly traded company in 2014 through a demerger. Since its separation, the company has evolved from a business heavily dependent on opioid dependence therapies toward a broader addiction science and neuropsychiatry platform. Its positioning is supported by established clinical expertise in addiction medicine, specialized commercialization capabilities in behavioral health, and a portfolio centered on long-acting injectable therapies designed to improve treatment adherence and patient outcomes.
SUPN Income Statement
SUPN Balance Sheet
SUPN Price History
SUPN Valuation
SUPN Dividends and Shares
SUPN Corporate Info
Rockville, MD 20850